Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial
Addiction · 2026
DOI: 10.1111/add.70521 ↗At a glance
Randomisierte kontrollierte Studie in Addiction, 2026. Written by John Marsden and 11 co-authors. Institution: Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Major MEDLINE topics: Buprenorphine, Craving, Opioid-Related Disorders, Opiate Substitution Treatment. 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: Indivior UK Limited.
Abstract (original language)
Aims
To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24‐week, multi‐centre, open‐label, superiority, randomised controlled trial comparing methadone or sublingual buprenorphine (MET/BUP‐SL) with extended‐release buprenorphine (BUP‐XR).
Participants
Adults with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition moderate to severe OUD ( n = 314; 98% severe). Mean age was 42 years, 32% were female and 44% were using non‐medical opioids, predominantly heroin, at study baseline. Intervention and comparator MET/BUP‐SL vs. BUP‐XR (1:1 randomisation).
Measurements
The outcome was the number of opioid‐free days (0–84) during weeks 13–24. Candidate mediators were visual analogue scale ratings of opioid ‘need’ and ‘want’ (VAS‐N, VAS‐W), craving imagery and intrusiveness [Craving Experiences Questionnaire – frequency version (CEQ‐F)] and personal functioning impairment [Work and Social Adjustment Scale (WSAS)]. Craving measures were assessed at baseline and weeks 4, 8 and 12, then reduced to binary summaries indicating craving absent at all follow‐up assessments vs. present at any assessment. WSAS was assessed at week 12 and retained as a continuous mediator.
Findings
During weeks 13–24, the adjusted mean number of opioid‐free days was 48.9 in the MET/BUP‐SL group and 58.5 in the BUP‐XR group [incidence rate ratio (IRR) = 1.20, 95% confidence interval (CI) = 1.10–1.30; P ‐value
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- South London and Maudsley NHS Foundation Trust, London, UK.
- NHS Tayside and Dundee Health and Social Care Partnership, Dundee, UK.
- Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK.
- Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
- North Wales Medical School, Bangor University, Bangor, Gwynedd, UK.
ORCID profiles: John Marsden, Mike Kelleher, Edward Day, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Zoë Hoare
Funding
- Indivior UK Limited
Cite
APA
Marsden, J., Kelleher, M., Cowden, F., Day, E., Dewhurst, J., Evans, R., Gilvarry, E., Lowry, N., Mitcheson, L., Murray, R., Quarshie, S., & Hoare, Z. (2026). Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial. Addiction. https://doi.org/10.1111/add.70521
Vancouver
Marsden J, Kelleher M, Cowden F, Day E, Dewhurst J, Evans R, et al. Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial. Addiction. 2026. doi:10.1111/add.70521
BibTeX
@article{Marsden2026,
author = {Marsden, John and Kelleher, Mike and Cowden, Fiona and Day, Edward and Dewhurst, Jonathan and Evans, Rachel and Gilvarry, Eilish and Lowry, Natalie and Mitcheson, Luke and Murray, Robert and Quarshie, Sophie and Hoare, Zoë},
title = {Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70521}
}
EUVIMED